Kiora Q2 2026 earnings: Cash runway is expected into late 2028

Kiora Pharmaceuticals (NASDAQ: KPRX) reported a second-quarter 2026 net loss of approximately $2.08 million, compared with $2.15 million a year earlier, while diluted loss per share narrowed to $0.34 from $0.54. Quarter-end cash and short-term investments totaled $16.8 million, and collaboration reimbursements continued to offset much of the spending associated with the KIO-301 clinical program.

Core financial results

Kiora did not report revenue in its quarterly income statement. Total operating expenses declined about 7.6% to $2.21 million, primarily because gross research and development expense fell as spending shifted away from preclinical and chemistry, manufacturing and controls activities toward clinical work.

R&D expense was $2.08 million before $1.34 million of collaboration credits from Théa, leaving a net R&D burden of approximately $0.74 million. That compares with approximately $0.90 million after credits in the prior-year quarter. General and administrative expense was nearly unchanged.

Clinical pipeline and business progress

KIO-301

Enrollment in the Phase 2 ABACUS-2 trial advanced into the higher 100-microgram dose cohort. The study is evaluating KIO-301 in patients with late-stage retinitis pigmentosa.

An independent safety review will take place after the first patients in the higher-dose cohort are treated and before enrollment of the remaining patients proceeds. Kiora expects the last patient’s first visit in the first quarter of 2027 and topline data in the third quarter of 2027.

Théa Open Innovation fully reimburses Kiora for ABACUS-2 development costs under the companies’ collaboration. Théa holds exclusive development and commercialization rights in the United States, Europe and certain other markets outside Asia, reducing Kiora’s direct financial burden while the trial progresses.

KIO-104

The Phase 2 KLARITY trial also continued enrollment in its higher-dose group. KIO-104 is being evaluated in patients with macular edema caused by retinal inflammation and has been well tolerated based on the safety information available to date.

Kiora expects initial clinical data in late 2026. The results are intended to assess activity across retinal conditions involving inflammation and macular edema and help determine the program’s next development stage.

Cash and financing support the projected runway

Cash and short-term investments increased to approximately $16.8 million from $13.9 million at March 31, 2026, a sequential increase of about 21%. Management attributed the change mainly to strategic equity financing completed during the quarter, partially offset by cash used in operations.

The private placement provides for up to $24.0 million in gross proceeds, but only $5.0 million was received upfront. The remaining approximately $19 million depends on the exercise of milestone-based warrants and therefore should not be treated as committed capital.

Based on its current operating plan, expected collaboration reimbursements and available capital, Kiora expects its resources to fund operations into late 2028. The company is also evaluating strategic transactions that could expand its pipeline and potentially satisfy a warrant-acceleration milestone.

Per-share loss improved much more than the underlying net loss

Kiora’s net loss narrowed by only about 3.4%, while diluted loss per share improved by approximately 37%. The difference largely reflects the 54.9% increase in weighted-average diluted shares to 6.18 million. Spreading the loss across a larger share base reduced the reported loss per share, so the EPS movement overstates the improvement in underlying profitability.

Risks investors need to watch

• Clinical timelines depend on trial execution and safety review. Enrollment of the remaining patients in ABACUS-2’s higher-dose cohort will proceed only after the predefined independent review.
• Clinical activity remains unproven. KIO-104 has been well tolerated based on available information, but its initial clinical activity data are not expected until late 2026. ABACUS-2 topline results are expected in the third quarter of 2027.
• Most private-placement proceeds remain conditional. Approximately $19 million of the potential financing depends on milestone-based warrant exercises rather than representing cash already secured.
• The cash-runway estimate relies on current assumptions. The late-2028 projection depends on Kiora’s operating plan, expected collaboration reimbursements and available capital.
• A strategic transaction may not be completed. Additional pipeline expansion and related warrant acceleration depend on the company successfully completing a potential transaction.

Summary

Kiora’s second-quarter operating loss narrowed as lower preclinical and manufacturing-related R&D spending reduced expenses, while Théa reimbursements continued to limit the cost of advancing KIO-301. Financing lifted quarter-end liquidity and supported management’s projected runway into late 2028, although most potential additional proceeds remain contingent. The next major operating checkpoints are initial KIO-104 data in late 2026 and continued progress toward ABACUS-2 topline results in the third quarter of 2027.